Reneuron Group (RENE)


RENE Share PerformanceMore

52 week high3.6750 05/12/16
52 week low1.7640 07/06/17
52 week change -1.2750 (-40.80%)
4 week volume70,123,270 27/05/17

Media for (RENE)

Presenter: Michael Hunt, CEO

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

ReNeuron says FDA okays cryopreserved hRPC formulation

ReNeuron Group said the US FDA has approved the cryopreserved formulation of its human retinal progenitor cell (hRP...

FDA approves cryopreserved hRPC formulation

RNS Number: 4005I ReNeuron Group plc 19 June 2017 AIM: RENE 19 June 2017 ReNeuron Group plc FDA approves cryopreserved formulation of ReNeuron's retinal stem cell therapy candidate New formulation enables expansion of Company's ophthalmology programmes ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the deve...

Notification of Preliminary Results

RNS Number: 4649H ReNeuron Group plc 08 June 2017 AIM: RENE 8 June 2017 ReNeuron Group plc Notification of Preliminary Results ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its preliminary results for the year ended 31 March 2017 on Thursday 29 June 2017. A m...

ReNeuron gets favourable feedback from US FDA

ReNeuron Group said it received favourable feedback from the US FDA at the End of Phase II meeting conducted in Apr...

Positive FDA feedback on proposed Phase III study

RNS Number: 0891H ReNeuron Group plc 05 June 2017 AIM: RENE 5 June 2017 ReNeuron Group plc ReNeuron progresses clinical and regulatory strategy for the US with stroke programme based on positive FDA regulatory feedback ReNeuron to apply for Special Protocol Assessment and Regenerative Medicine Advanced Therapy designation as part of US Phase ...

ReNeuron presents positive exosome data

ReNeuron Group will be presenting new positive pre-clinical data relating to its ExoPr0 CTX cell-derived exosome therapy...

Presents positive exosome data at major conference

RNS Number: 4700F ReNeuron Group plc 18 May 2017 AIM: RENE 18 May 2017 ReNeuron Group plc ReNeuron presents positive pre-clinical data with its ExoPr0 exosome therapy candidate at major scientific conference Data show that ExoPr0 can cross the blood brain barrier and can potentially target multiple diseases via local or systemic administration ReNeur...

ReNeuron awarded £1.8m grant from Innovate UK

ReNeuron Group has been awarded a 1.8m grant from Innovate UK to further advance its next generation commercial ce...

Fundamental DataMore

Dividend yield0 %

Equity Research (RENE)

edison investment research
ReNeuron Group plc
ReNeuron continues to prepare for its Phase III chronic stroke study (due to start in H217) and has indicated that it is making progress with the US/EU regulatory authorities. It intends to submit an...
edison investment research
ReNeuron Group plc
ReNeuron reported in December 2016 positive Phase II trial data for its CTX cells in chronic stroke patients, despite not meeting the three-month time frame of a two-point improvement in its primary...
edison investment research
ReNeuron Group plc
ReNeuron has presented positive Phase II trial data for its CTX cells in chronic stroke patients. Reported data included 15 out of 21 patients having a clinically relevant and sustained response on...

Latest discussion posts More

  • Re: ANYONE Buying ?

    Just found another interesting article albeit Jan 2017
  • Re: ANYONE Buying ?

    Hi Loper. I've failed at the first hurdle. When I get to the headline and click it states 'You don't have access to this information' I've tried joining the site but won't ...
  • Re: ANYONE Buying ?

    - see " Traders panic into safe haven biotechs -------" - June 21 st, 4.01 pm

Users' HoldingsMore

Users who hold Reneuron Group also hold..

Codes & Symbols